Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for RMTI
-0.09 (-1.58%)
After Hours: 5.71 +0.09 (1.60%)
Feb 20, 5:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.48 - 5.73
52 week 4.84 - 8.98
Open 5.66
Vol / Avg. 0.00/268,392.00
Mkt cap 290.90M
P/E     -
Div/yield     -
EPS -0.43
Shares 51.76M
Beta 2.16
Inst. own 32%
Mar 13, 2018
Q4 2017 Rockwell Medical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -34.57% -37.16%
Operating margin -34.36% -37.93%
EBITD margin - -36.50%
Return on average assets -29.99% -23.16%
Return on average equity -47.93% -34.36%
Employees 300 -
CDP Score - -


30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company's drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Thomas E. Klema CPA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 63
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Raymond Dennis Pratt M.D. Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Patrick J. Bagley Lead Independent Director
Age: 51
Bio & Compensation  - Reuters
John G. Cooper CPA Director
Age: 59
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 54
Bio & Compensation  - Reuters
David T. Domzalski Independent Director
Age: 50
Bio & Compensation  - Reuters
Robin L. Smith M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters